The lack of a relevant, tractable, and immunocompetent animal model for hepatitis C virus (HCV) has severely impeded investigations of viral persistence, immunity, and pathogenesis. In the absence of immunocompetent models with robust HCV infection, homolog hepaciviruses in their natural host could potentially provide useful surrogate models. We isolated a rodent hepacivirus from wild rats (Rattus norvegicus), RHV-rn1; acquired the complete viral genome sequence; and developed an infectious reverse genetics system. RHV-rn1 resembles HCV in genomic features including the pattern of polyprotein cleavage sites and secondary structures in the viral 5 0 and 3 0 untranslated regions. We used site-directed and random mutagenesis to determine that only the first of the two microRNA-122 seed sites in the viral 5 0 untranslated region is required for viral replication and persistence in rats. Next, we used the clone-derived virus progeny to infect several inbred and outbred rat strains. Our results determined that RHV-rn1 possesses several HCV-defining hallmarks: hepatotropism, propensity to persist, and the ability to induce gradual liver damage. Histological examination of liver samples revealed the presence of lymphoid aggregates, parenchymal inflammation, and macrovesicular and microvesicular steatosis in chronically infected rats. Gene expression analysis demonstrated that the intrahepatic response during RHV-rn1 infection in rats mirrors that of HCV infection, including persistent activation of interferon signaling pathways. Finally, we determined that the backbone drug of HCV direct-acting antiviral therapy, sofosbuvir, effectively suppresses chronic RHV-rn1 infection in rats. Conclusion: We developed RHV-rn1-infected rats as a fully immunocompetent and informative surrogate model to delineate the mechanisms of HCV-related viral persistence, immunity, and pathogenesis. (HEPATOLOGY 2018; 68:435-448).
H epatitis C virus (HCV) is a hepatotropic
RNA virus classified within the genus Hepacivirus of the family Flaviviridae and a leading cause of chronic liver disease globally. Following acute infection, HCV establishes lifelong persistence in 60%-80% of individuals, significantly elevating the risk for developing liver cirrhosis and hepatocellular carcinoma.
(1) The host and viral determinants governing this acute to chronic transition of HCV infection are mostly unknown, in large part due to the absence of immunocompetent animal models for its in vivo characterization. (2) Beside humans, HCV only infects chimpanzees; and therefore, unlike the in-depth in vitro characterization, most of our knowledge of HCV pathogenesis and immunity is gained through studies of infected humans or experimentally infected chimpanzees, limited by either the lack of appropriate human samples or an insufficient number of animals to Abbreviations: ALT, alanine aminotransferase; DAA, direct-acting antiviral; DEG, differentially expressed gene; GBV-B, GB virus B; HCV, hepatitis C virus; HTZ, Holtzman; IFN, interferon; IL, interleukin; MHC, major histocompatibility complex; miR-122, microRNA 122; NS3/4, nonstructural proteins 3/4; RHV-rn1, rodent hepacivirus from Rattus norvegicus; RNA-seq, RNA sequencing; UTR, untranslated region.
enable an unambiguous analysis. Furthermore, the use of chimpanzees in the elucidation of host response patterns against HCV and for the testing of preclinical therapeutic and vaccine modalities has been stopped or restricted in most countries because of ethical considerations. Thus, a relevant, tractable, and immunocompetent animal model is urgently needed if the mechanisms behind HCV pathogenesis unique to humans are to be deciphered. (3, 4) GB virus B (GBV-B), a hepacivirus of mysterious origin, is a well-recognized HCV surrogate model but unlike HCV, it usually causes only acute resolving infections in tamarins. (3, 5) Nonetheless, GBV-B infection in tamarins helped in elucidating the functional importance of several viral genome features including the relevance of microRNA-122 (miR-122) binding sites in the viral 5 0 untranslated region (UTR) and the importance of different sequence elements of the 3 0 UTR. (6, 7) Over the years several genetically engineered mouse models of HCV have been described, but in addition to being technically cumbersome, these platforms suffer from an underlying requirement to blunt innate and/or adaptive immune responses to support even mediocre levels of viral replication, precluding detailed analysis of HCV-associated immunity. (8, 9) Recently, we and others have identified multiple hepacivirus species in wild rodents. (10) These rodent hepaciviruses share common genetic and evolutionary features with HCV and therefore, with their natural hosts, could provide relevant surrogate models for the study of HCV. (11) The animal host of an ideal surrogate, however, should be an accessible and wellcharacterized laboratory model with numerous molecular and genetic tools available for examining the mechanisms of viral pathogenesis. For this reason, we chose to establish a model system using a variant of a hepacivirus species identified during a metagenomics survey of pathogens in Norway rats (Rattus norvegicus). (12) We determined that this rat hepacivirus isolate, RHV-rn1, fails to establish persistent infection in immunocompetent laboratory mice. (13) Here, we describe that RHV-rn1 infection in laboratory rats mirrors HCV infection in humans and therefore provides an informative, tractable, and fully immunocompetent surrogate model for studies of HCV persistence, immunity, and liver pathogenesis.
Materials and Methods

ANIMALS
Brown Norway, Sprague-Dawley, Wistar Han, Holtzman (HTZ), and Long-Evans rats were obtained from commercial suppliers (Charles River or Envigo). All animal studies were performed at North Carolina State University and The Research Institute at Nationwide Children's Hospital using protocols approved by respective Institutional Animal Care and Use Committees.
VIRAL GENOME, INFECTIOUS CLONE, MUTAGENESIS, AND RNA TRANSCRIPTION
The complete genome of RHV-rn1 was sequenced as reported by us for other rodent hepaciviruses. (14, 15) The RHV-rn1 molecular clone was synthesized and modified to introduce desired restriction sites using standard molecular techniques. Site-directed and random mutagenesis was performed using commercial PCR mutagenesis kits (New England Biolabs). After linearization of the plasmid, viral transcripts were synthesized using the Hi-Script Transcription kit (Promega). After a DNAase-I digestion step, purified RNA was used for intrahepatic injection into rats. The complete genome of RHV-rn1 is deposited in GenBank (accession no. KX905133).
RHV-rn1 INFECTION, VIRAL TITERS, AND ANTIBODY DETECTION
Rats were infected intravenously with 10 5 -10 7 virus genome equivalents of RHV-rn1 by tail vein injection. For experiments involving the RHV-rn1 molecular clone, animals were injected intrahepatically with 5 lg of purified RNA.
Viral RNA from animal sera was extracted using the QIAamp Viral RNA Mini Kit (Qiagen). After reverse transcription, quantitative PCR was done using AmpliTaq Gold 360 Master Mix (Applied Biosystems) and the following cycling conditions: 508C for 2 minutes, 958C for 2 minutes, and 40 cycles of 958C for 15 seconds, 538C for 45 seconds, and 608C for 45 seconds. Primers and probe sequences used for this protocol were TACATGGCTAAGCAATACGG (sense), AAGCGCAGCACCAATTCC (antisense), and CTCACGTACATGACGTACGGCATG[B HQ1a-6FAM] (probe). To detect negative-strand RNA replicative intermediates, we used a RNA polyuridylation approach. Briefly, total RNA was polyuridylated through poly-U polymerase (New England Biolabs), followed by complementary DNA generation using Superscript II Reverse Transcriptase and a unique primer containing a polyadenylated 3 0 end (GAATCGAGCACCAGTTACGCATGCCGAG GTCGACTTCCTAGAAAAAAAAAAAAAAAA-AACCA). PCR was then performed using a truncated form of the unique reverse-transcriptase primer (GAATCGAGCACCAGTTACG) and an RHVrn1-specific negative-strand primer (CCATGTAGA GGAGATAAGTCC).
To detect antibody responses in infected animals, we used a sensitive luciferase immunoprecipitation system assay to screen serum samples for the presence of antibodies against the RHV-rn1 nonstructural protein 3 (NS3) helicase protein. A 240-amino acid fragment (positions 1139-1379) of the RHV-rn1 helicase protein (NS3) was subcloned downstream of Renilla luciferase using the pREN2 vector to express Renilla luciferase-fused viral antigen. Luciferase immunoprecipitation system assays were performed as described in our previous publications. (16) 
TISSUE HISTOLOGY
Liver sections (6 lm) were fixed with 10% neutral buffered formaldehyde, processed routinely, and stained using hematoxylin and eosin. In situ hybridization was performed using RNAscope and a probe targeting RHV-rn1 helicase sequence.
SERUM ALANINE AMINOTRANSFERASE QUANTIFICATION
Serum alanine aminotransferase (ALT) levels in rats were determined using an ALT assay kit (BioScientific) per the manufacturer's instructions.
RNA SEQUENCING ANALYSIS OF INFECTED LIVER SAMPLES
Liver sections and biopsies were immediately immersed in RNAlater (Ambion) and kept at -808C until RNA extraction using the RNeasy kit (Qiagen). DNA and ribosomal RNA from total RNA were removed using DNAse-I and Ribo-zero (Illumina), and then samples with RNA integrity values >7 were used for RNA sequencing (RNA-seq). We used Illumina Scriptseq (stranded RNAseq) for library preparation and paired end 150-bp SBS Chemistry to generate sequences using the Illumina HiSeq4000 platform. Sixty million reads were generated for each liver sample. Quality filtering of reads was done using FastQC (v0.11.3), and then sequences were mapped to the reference genome of R. norvegicus, from the National Center for Biotechnology Information's Rnor_6.0 (ftp://igenome:G3nom3s4u@ussd-ftp.illumina.com/Rattus_norvegicus/NCBI/Rnor_6.0/Rattus_ norvegicus_NCBI_Rnor_6.0.tar.gz) using TopHat2 (v2.1.1). The Cufflinks v2.2.1 package was used for transcript assembly and calculation of differential gene expression. The Cuffmerge (v1.0.0) tool was used to merge and generate a combined transcript. Merged transcript and reference genome fasta were used by the Cuffdiff (v2.2.1) tool to generate differential gene expression for any two different sample conditions. RNA-Seq analysis was performed using a previously described protocol. (17) Gene function and pathway analysis was performed by Ingenuity Pathway Analysis software (Qiagen Inc.). Cutoff parameters used to identify differentially expressed genes (DEGs) were P < 0.05, false discovery rate q < 0.05, and fold change >0.5849. (14) We used custom in-house-developed Rscripts and R-packages, Limma for Venn diagram and gplots for making heatmaps.
Results
ISOLATION, GENOME SEQUENCING, AND REVERSE GENETIC SYSTEM FOR RHV-rn1
Because only a partial genome of the rodent hepacivirus has been sequenced, (12) we first infected four Sprague-Dawley rats with a serum sample from an RHV-rn1-infected wild rat. All infected rats developed high-titer viremia at 1 week postinfection and remained viremic for the entire duration of the study (80 days postinfection) (Fig. 1A) . A terminal serum sample of a chronically infected female rat was then used to acquire the complete viral genome using nextgeneration sequencing (Illumina HiSeq). After de novo assembly of the viral genome, the polyprotein coding sequence was reconfirmed by Sanger dideoxy sequencing. Thereafter, both genomic termini were acquired using a rapid amplification of complementary DNA ends and a phosphorylated oligonucleotide adapter ligation approach for the 5 0 and 3 0 ends, respectively. (14, 15) The resulting viral genome was henceforth termed "RHV-rn1" as it shared 8,450/8,975 (94%) nucleotide and 2,936/2,991 (98%) amino acid identities with the published partial genome sequence of the Norway rat hepacivirus (GenBank accession no. KJ950938).
The complete genome of RHV-rn1 contains 9,656 nucleotides and encodes a single 2,991-amino acid long polyprotein (GenBank accession no. KX905133; Fig.  1B ). Cleavage sites documented for HCV are conserved in RHV-rn1 and allowed a robust prediction of the sizes of the replication-associated proteins; a separate analysis using signalaseP (18) predicted cleavage sites that would produce core, E1, E2, and p7 proteins comparable in size to those of HCV and other hepaciviruses (Fig. 1B) . The 5 0 UTR is 485 bases long and terminates with a methionine codon in the optimal Kozak context. The 3 0 end of the 5 0 UTR is predicted to form a type IV internal ribosomal entry site despite a high degree of sequence divergence with HCV and other hepaciviruses in this region (Fig. 1C) . Furthermore, the 5 0 UTR of RHV-rn1 contains two miR-122 seed sites (CACUCC), which are important for HCV replication and hepatotropism. (19, 20) The 3 0 UTR is 297 bases long and contains a short poly-C region followed by three stem loops (SLI-SLIII) and a U as terminal base, similar to the HCV 3 0 X region (Supporting Fig. S1 ).
Next, we constructed a complete genomic clone of RHV-rn1 using the consensus sequence described above ( Fig. 2A) . To test the infectivity of clonederived transcripts, we injected 5 lg of RHV-rn1 RNA directly into the livers of immunocompetent brown Norway rats. All inoculated rats developed high-titer viremia at 3 days postinfection and remained viremic throughout the study period (>17 weeks postinfection) (Fig. 2B) . Injected rats developed anti-NS3 immunoglobulin G within 3-4 weeks postinfection No significant fluctuations in serum ALT levels were observed. In situ hybridization using an RHV-rn1 helicase-specific probe showed the presence of viral genomes in the cytoplasm of hepatocytes (Fig. 2C) . Comparison of viral titers in different organs and a negative-strand RNA assay further confirmed the hepatotropic nature of the virus (Fig.  2D,E) . Sequencing of serum virus from infected rats showed 100% nucleotide identity to the plasmid clone. A serum sample from one rat with high-titer viremia was then used to infect eight naive rats, all of which developed persistent infection (data not shown). Together, these results confirmed that the RHV-rn1 clone contains all necessary genomic elements to produce infectious virus.
IMPORTANCE OF THE TWO miR-122 SEED SITES IN THE VIRAL 5
0 UTR
The RHV-rn1 reverse genetics system provides an unlimited resource to generate natural and mutant viruses for the functional and biological characterization of different genomic features. As a proof of principle, we next focused our studies on the functional role of the two miR-122 binding sites within the viral 5 0 UTR. First, we created two pools of RHV-rn1 mutant plasmids, RM-1 and RM-2, using random mutagenesis of either of the two miR-122 seed sites (Fig. 3A) . RNA transcripts of these pools were sequenced to confirm an approximately equimolar presence of all four ribonucleotides at the six base positions theoretically generating 4,095 unique mutants in each pool. Then, 5 lg of RM-1 and RM-2 transcripts were separately injected into the liver of individual brown Norway rats. Both rats developed a high-titer viremia 3 days postinfection and remained persistently infected for the duration of the study period (82 days postinfection). All serial serum samples of the RM-1-injected rat, including the earliest sample (3 days postinfection), showed RHV-rn1 variants with the natural miR-122 seed site sequence (CACUCC), indicating strong selection for this seed site (Fig. 3B) . However, all serial serum samples of the RM-2-injected rat showed selection of an RHV-rn1 variant containing a unique sequence (ACAGUG-U) in place of the canonical miR-122 seed site sequence (Fig. 3B) . Even the earliest appearing serum virus, 3 days postinfection, had this unique sequence, indicating rapid selection of this variant. Interestingly, this sequence remained unchanged until the end of the study (90 days postinfection), indicating the dispensability of the second miR-122 seed site for viral replication and persistence. To further confirm, we infected two more rats with RM-2. Both of these rats developed viremia, but, interestingly, the sequencing of serum virus showed a swarm of RM-2 variants at 3-13 days postinfection in one rat and up to 23 days postinfection in the other; after that only the wild-type RHV-rn1 (CACUCC) was present in both rats. Although these results indicated the dispensability of the second miR-122 seed site for RHV-rn1 infection, this seed site apparently also conferred a replication advantage to the virus.
Next, we used site-directed mutagenesis to confirm the requirement of the first miR-122 seed site sequence (Fig. 3A) . Rats infected with SM-3 (auxiliary pairing mutant) and SM-12 (seed site mutant) viruses showed an early appearance of viremia that persisted for the duration of the study period (90 days postinfection, Fig.  3C ). While the SM-3 virus did not revert back to the wild-type sequence, the SM-12 virus reverted back in all three infected animals after 10 days. The SM-3 viruses maintained an intact binding site 1 for miR-122. To confirm that the SM-12 reversion is not due to the disruption of a small predicted stem loop structure, we created a double mutant virus where position 21 was changed to pair with the mutated SM-12 site. Interestingly, this double mutant failed to induce infection or seroconversion in the two injected rats. Taken together, these results indicate that only the first canonical miR-122 seed site is crucial for the virus in vivo; however, the cytidine residue at the third position in the RHVrn1 genome, predicted to bind the 3 0 region of rat miR-122, has no effect on viral replication and persistence. Interestingly, mutations at the SM-3 site in HCV can confer resistance against the miR-122 antagomir in humans. 
INFECTION OUTCOMES AND LIVER DISEASES IN LABORATORY RATS
While brown Norway rats provide an exceptional in vivo platform for evaluating the role of viral genomic features, we failed to observe even partial control of RHV-rn1 infection in this inbred strain. To evaluate whether host heterogeneity influences RHV-rn1 infection outcome, we infected four different outbred lines of rats: Sprague-Dawley, HTZ, Long-Evans, and Wistar Han. While Long-Evans, Wistar Han, and Sprague-Dawley rats showed limited suppression of viral replication, HTZ rats exhibited clear differences in viral titers between individuals within the first 80 days of infection (Fig. 4) . Because HTZ rats displayed the largest suppression of viremia, four rats of this strain were kept for a longer period to study the viral persistence and development of liver diseases. All six infected rats also showed elevation of ALT that fluctuated over time similar to HCV infection in humans   FIG. 4 . RHV-rn1 infection and outcomes in outbred rat strains. Six rats of each strain were infected with 10 6 genomic copies of the clone-derived RHV-rn1. Abbreviation: VGE, virus genome equivalents. In the three SM-3-infected rats, the mutant virus remained mutant type, while in the three SM12-infected rats, the mutant virus reverted back to wild type after 10 days postinfection. The double mutant with complementary SM12 and SM21 mutations failed to initiate infection in the two injected rats (pink line). Abbreviation: VGE, virus genome equivalents.
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( Fig. 5A) . (23) One of the four rats started suppressing the viremia around day 150 and achieved complete virus clearance by day 275. This rat (no. 52) remained clear of virus for the duration of the study (325 days), indicating complete and spontaneous resolution of viral infection (Fig. 5A) .
To study the histopathological changes in the livers of infected rats, two serial liver biopsies were obtained from four infected rats (nos. 49, 50, 52, and 53) at days 85 and 235. A third liver biopsy was collected from one rat (no. 49) on day 287 to confirm continued progression of liver diseases. At day 85 postinfection, all four infected rats exhibited moderate hepatic inflammation characterized by a consistent pattern of dense lymphocytic aggregates focused on the portal tracts. At this stage there was focal evidence of extension of the inflammation beyond the margins of the limiting plate, indicative of mild piecemeal necrosis (Fig. 5B) . At day 235 postinfection the histologic features of the livers had changed, with evident but diminished portal tract lymphoid infiltrates. At this point there was more parenchymal damage with hepatic plate disarray and isolated lymphocytic foci within the hepatic parenchyma and often associated with apoptotic hepatocytes. Another feature evident in the later biopsies and characteristic of human HCV infection was the presence of both macrovesicular and microvesicular steatosis in hepatocytes. Bile ducts were indistinct in scattered portal tracts, suggesting injury, but clearly evident injury to the ducts was rare. Next, we used in situ hybridization to colocalize virus and liver pathological changes. Interestingly, we found steatosis in the hepatocytes infected with the virus, suggesting that virus replication can directly trigger steatosis in hepatocytes (Fig. 5C ).
INTRAHEPATIC RESPONSES DURING RHV-rn1 INFECTION
HCV infection is known to induce potent liver responses during acute as well as chronic infection. (22) (23) (24) (25) We used RNA-seq analysis of liver samples collected on days 20, 85, and 235 postinfection from HTZ rats of two different major histocompatibility complex (MHC) class-I haplotypes, RT-1 l and RT-1 u . Comparison of DEGs between infected and uninfected rats indicated an increased number of DEGs in the later phase of infection (Fig. 6A,B) . Uninfected rats with different class-I molecule shared 200-285 of the DEGs; most of these were involved in metabolism and physiological processes. Interestingly, we identified 416 and 457 DEGs unique to infected rats with RT-1 l and RT-1 u genotypes, respectively. Analysis of the predicted biological functions of these DEGs revealed their primary role in cellular and host responses against viral infection, including higher expression of several DEGs involved in the interferon (IFN) signaling pathway (Fig. 6C) . We further identified 123 DEGs that were exclusive to the infected rats of both genotypes. These DEGs include genes primarily involved in leukocyte and interleukin (IL) signaling. Upstream regulators included IFN-c, tumor necrosis factor, colony-stimulating factor 2, IL-6, myeloid differentiation factor 88, signal transducer and activator of transcription 1, and IL-2. Noticeably, while MHC class-II molecules were consistently overexpressed after RHV-rn1 infection, the class-I molecules were significantly repressed, albeit with an inconsistent pattern (Fig. 6C) .
Notably, the magnitude of RHV-rn1-induced DEGs of IFN pathways increased during the late phase of infection, indicating the persistent nature of the antiviral host responses (Fig. 7A,B) . DEGs shared among class-I, class-II, and class-III IFNs were most significantly overexpressed, including OASL, OAS3, CXCL10, TNFRSF14, STAT1, STAT4, IRF7, and IFITM3. Increased IL-8 signaling was noticed in the liver at days 85 and 235 postinfection, indicating an increase in angiogenesis and inflammation. There was a significant increase in the expression of genes that are known to play a role in pattern recognition receptor signaling, like TLR7, TLR8, MDA-5, NALP3, PKC, IRF7, NFKB, and RANTES. Suppressed biological pathways included RhoGDI signaling and liver X receptor activation. HCV infection in vitro leads to sequestration of cellular miR-122. (28) Our RNA-seq data on rats with the RT-1 l haplotype indicated derepression of a number of miR-122-regulated genes (ACTR1A, CCNG1, CREB1, CYP2C9, GIT1, GNPDA1, 1QGAP, KHDRBS1, LAMC1, MAP4, MTHFD2, PKM, PTPN1, RBM3, SEMA4D, SEPT2, SH3GRL3, VAV3, and VIM). However, derepression of DEGs was also observed for genes regulated by miR-21 and the let-7 cluster in the livers of infected rats. While there were no significant differences in the expression levels of known HCV entry factors (SCARB1, CD81, CLDN1, and OCLN), expression of a recently identified entry factor, cadherin, was consistently increased in the livers of all infected rats. (29) 
RHV-rn1-INFECTED RATS AS A MODEL FOR HCV DIRECT-ACTING ANTIVIRAL THERAPY
To assess the feasibility of our rodent hepacivirusinfected rat model to study changes in the viral population and virus-specific T-cell immunity after directacting antiviral (DAA) cure, we treated three rats with established chronic RHV-rn1 infection with sofosbuvir and ribavirin (Fig. 8) . Daily doses of sofosbuvir (40 mg/kg) and ribavirin (70 mg/kg in two doses) were comparable to the recommended human doses adjusted to rat pharmacokinetics. As controls, three chronically infected rats were treated with only ribavirin and one rat was put on low-dose sofosbuvir (5 mg/ kg/day) and ribavirin. Our results unambiguously showed that the high-dose sofosbuvir and ribavirin combination rapidly suppressed RHV-rn1 replication to below the detection threshold in all three treated rats. Low-dose sofosbuvir with ribavirin and ribavirin alone failed to suppress the viremia in treated rats. Interestingly, the viremia rapidly rebounded in all three rats 1 week after the drugs were discontinued (Fig. 8) , suggesting that a longer period of high-dose sofosbuvir and ribavirin treatment is required to achieve a sustained viral response in rats.
Discussion
We isolated RHV-rn1 from samples of a wild rat, developed an infectious clone, and produced homogenous virus stocks to infect several strains of laboratory rats, expecting to develop an informative model to study HCV-like viral persistence and liver diseases. Our results show that infected rats spontaneously develop chronic hepacivirus infections, making this model of hepacivirus infection in its natural host of great relevance for understanding human HCV infection and immunity. We further determined that RHV-rn1 is hepatotropic and that chronic viral infection leads to slow progressive liver diseases (Fig. 2) .
Development of an infectious clone for RHV-rn1 will allow studies of virus mutagenesis and facilitate the development of in vitro systems. Similar developments for HCV took several years, mainly due to failure to identify the 3 0 end of the viral genome and lack of a tractable model. (30) We recently established a similar system for the equine nonprimate hepacivirus in horses. (15) We used our reverse genetic system to study the biological importance of miR-122 sites in the 5 0 UTR of RHV-rn1. Our results indicate that only the first of the two miR-122 sites is indispensable for RHV-rn1 replication and persistence. We also used a random mutagenesis approach that allowed identification of an RHV-rn1 variant with a unique sequence in place of the second miR-122 seed site. Further studies using these different viruses, with one or both of the wild-type miR-122 sites, may shed new light on their role in virus infection outcomes and pathogenesis. Recently, miR-122 "sponging" by HCV genomes has been suggested to play a role in regulating the gene expression of miR-122 target genes in hepatocytes, including oncogenes, thereby providing an environment fertile for endstage liver diseases such as hepatocellular carcinoma. (28) Here, we showed derepression of selected miR-122 targets in infected rats. RHV-rn1 miR-122 mutants will be useful to study the derepression of Host factors play an important role in determining the infection and the pathogenic outcomes of HCV infections in humans. (2, 31) While 20%-30% of infected individuals clear the virus within the first year of infection, the remaining 70%-80% of individuals develop a lifelong chronic virus infection. (1, (32) (33) (34) The acute phase of HCV infection in humans is generally asymptomatic with the exception of mild elevations in serum ALT levels indicating liver injury. (35) After several years of chronic infection, some of these patients develop liver diseases including chronic hepatitis, steatosis, fibrosis, cirrhosis, and hepatocellular carcinoma. (36) The variables that can dictate or contribute to these differences remain unknown, largely due to lack of a fully immunocompetent tractable model. Here, we used homogenous virus stock derived from our reverse genetics system, yet the infected HTZ rats differed in the course of viremia, infection outcomes and liver pathology (Fig. 5) , resembling HCV infection in humans. Thus, we believe that RHV-rn1 infection in outbred or genetically heterogeneous rats provides a unique model to identify host determinants of hepacivirus infection outcomes and pathogenesis.
HCV liver disease is characterized by the histologic triad of lymphoid aggregates in portal tracts, epithelial damage of small bile ducts, and microvesicular and macrovesicular steatosis of hepatocytes. (37) We determined that RHV-rn1-infected rats develop two of these three features with a suggestion of biliary epithelial injury as well within 32 weeks postinfection. The presence of macrovesicular and microvesicular steatosis in livers of RHV-rn1-infected rats is a finding of major significance. We used in situ hybridization to determine that several virus-infected hepatocytes had steatosis, suggesting direct induction by virus infection (Fig. 5C ). Uninfected rats and one of the infected rats did not develop steatosis. More interestingly, in rat no. 52, virus clearance led to reversion of inflammation, confirming the direct link with the virus. Many human patients with chronic HCV also develop a degree of hepatic steatosis. Moreover, several clinical studies have now confirmed that hepatic steatosis is an independent risk factor of hepatocellular carcinoma in patients with chronic HCV. (38, 39) Development of parenchymal inflammation, hepatitis, necrosis, and steatosis within 8 months of RHV-rn1 infection indicates that some chronically infected rats could consequently progress to cirrhosis and hepatocellular carcinoma.
In vitro studies of HCV suggest that the viral NS3/ 4A protease can block IRF3-mediated transcriptional activation of IFN-b by cleavage and inactivation of the mitochondrial antiviral signaling and TIR domaincontaining adapter proteins. (40, 41) However, strong innate immune responses are observed in humans and chimpanzees infected with HCV. (24, 27, 42, 43) Notably, HCV is known to induce stronger innate immune responses than the other mitochondrial antiviral signaling-cleaving hepatotropic RNA virus, hepatitis A virus. (24) (25) (26) (27) Moreover, chronic liver inflammation during HCV infection contributes toward a procarcinogenic microenvironment and paves the way for development of fibrosis/cirrhosis and hepatocellular carcinoma. (44) Our liver transcriptomics of RHV-rn1-infected rats during acute and chronic phases shows significant overexpression of genes associated with inflammatory responses. Interestingly, the magnitude of IFN-stimulated gene expression increased during the chronic phase compared to the early infection phase, indicating persistent activation of IFN and innate immune responses during RHV-rn1 infection. Additionally, several signaling pathways of the adaptive immunity were persistently activated. Differentiation of naive T cells requires antigenic stimulation mediated by the T-cell receptor and coreceptor CD4 with the antigen-MHC-II complex. IL-2 and IFN-c are the two most important cytokines for Th1 differentiation. (45) Our results indicate persistent activation of the Th1 pathway during RHV-rn1 infection in rats despite their failure to clear the viral persistence. Virus-specific functional T-cell responses against core, NS3, and NS4 proteins were also detected using IFN-c-ELISpot assays in RHV-nr1-infected HTZ rats (data not shown). MHC class-II molecules were found significantly overexpressed. Interestingly, our data showed repression of class-I molecules, the expression of which is necessary for effective targeting of infected hepatocytes by cytotoxic CD8 1 T cells. Overall, these results confirm that RHV-rn1-infected rats offer a suitable in vivo platform to elucidate the role of various IFNstimulated genes and immune responses in hepacivirus pathogenesis. Notably, RNA-seq analysis of outbred animals is challenging due to inherent differences in host genetics, and therefore, our data need to be confirmed using a lager cohort of infected rats and MHC-matched controls.
An IFN-free regimen of DAAs can achieve sustained virologic response in most HCV-infected subjects. (46) Considering that persistent antigenic
